Fig. 6

Influence of PDE5 Inhibitor Tadalafil on Prostatic Tissue Fibrosis within the PDE Model. (A) Illustration outlining the construction process of the PDE model. (B) Masson’s trichrome staining to evaluate the effect of tadalafil treatment (25µM) on prostate tissue fibrosis. (C) qRT-PCR comparison of miR-3126-3p expression levels between the tadalafil treatment tissues (25µM) and the control tissues. (D) Western blot analysis to detect the protein expression levels of Collagen I, αSMA, and IGFBP3 in the control group and the tadalafil treatment (25µM) group across the three PDE models. (E) Immunohistochemical assessment of αSMA staining density in PDE model after tadalafil treatment (25µM). (F) Evaluation of IGFBP3 expression by immunohistochemical analysis in the PDE model following tadalafil treatment (25µM) (n = 3). (G) Immunohistochemical investigation of FGF9 expression in the PDE model following tadalafil treatment (25µM) (n = 3). Values are presented as mean ± SD. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001)